(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...
Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...
A simplified schematic illustrating how cancer cells evade immune attack by expressing PD-L1, which binds to PD-1 on T cells and suppresses their activity. The figure also shows how immune checkpoint ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
SCLC, adding PD-1 or PD-L1 inhibitors to platinum-etoposide in the first line consistently improves survival outcomes.
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...
Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results